Loading clinical trials...
Loading clinical trials...
Animal and human studies have brought up evidence supporting Gut microbial disbalance, namely dysbiosis, as a causative factor of epilepsy, especially the refractory form. thus, probiotics might constitute a safe, low-cost, and effective supplementary therapy in patients with DRE. The Lactobacillus population is probiotic bacteria that have a beneficial role in epilepsy. Lactobacillus can influence brain function through the modulation of GABA, as shown in rodent models. Moreover, it has been demonstrated in animal models of epilepsy and in human epileptic patients that probiotic treatment aimed at restoring gut microbiota equilibrium has beneficial effects on epileptic symptoms by increasing GABA in animals and the levels of Bifidobacteria and Lactobacillus in humans.
This study will be a placebo-controlled, double-blind, and parallel 6-month duration study
Age
3 - 18 years
Sex
ALL
Healthy Volunteers
No
Amira
Tanta, Egypt
Start Date
September 25, 2022
Primary Completion Date
August 5, 2024
Completion Date
February 1, 2025
Last Updated
July 1, 2025
60
ACTUAL participants
Lactobacillus-Based Capsule
DRUG
Lead Sponsor
Tanta University
NCT03268824
NCT05019885
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions